KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBT Margin (2016 - 2025)

Vertex Pharmaceuticals has reported EBT Margin over the past 17 years, most recently at 41.72% for Q4 2025.

  • Quarterly results put EBT Margin at 41.72% for Q4 2025, up 270.0% from a year ago — trailing twelve months through Dec 2025 was 38.69% (up 3643.0% YoY), and the annual figure for FY2025 was 38.69%, up 3643.0%.
  • EBT Margin for Q4 2025 was 41.72% at Vertex Pharmaceuticals, down from 42.22% in the prior quarter.
  • Over the last five years, EBT Margin for VRTX hit a ceiling of 54.57% in Q3 2021 and a floor of 128.18% in Q2 2024.
  • Median EBT Margin over the past 5 years was 44.84% (2022), compared with a mean of 33.22%.
  • Biggest five-year swings in EBT Margin: plummeted -17477bps in 2024 and later skyrocketed 17146bps in 2025.
  • Vertex Pharmaceuticals' EBT Margin stood at 42.02% in 2021, then rose by 11bps to 46.76% in 2022, then decreased by -3bps to 45.58% in 2023, then fell by -14bps to 39.03% in 2024, then increased by 7bps to 41.72% in 2025.
  • The last three reported values for EBT Margin were 41.72% (Q4 2025), 42.22% (Q3 2025), and 43.28% (Q2 2025) per Business Quant data.